adhesion, and aggregation processes that must be tightly regulated to prevent thrombotic disorders and to assure rapid hemostasis in case of traumatic injuries (2) . Part of this regulation is based on reversible, posttranslational protein modifications. While many studies have focused on the role of protein phosphorylation during platelet activation, less is known about the functional impact of protein lysine acetylation. The paper by Aslan and colleagues in this issue (1) focuses on the role of tubulin acetylation during platelet activation.
The discoid shape of quiescent platelets is maintained by the marginal band, a microtubular ring structure localized circum- Fig. 1 . Putative sequence of events during platelet activation. A: quiescent discoid platelet. HDAC6, histone deacetylase 6; SFK, Src family kinases; PAK, p21-activated kinase; GPVI, glycoprotein VI. B: stimulation of platelet activation with collagen-related peptide (CRP) leads to the activation of SFKs necessary for platelet shape change. C: disc-to-sphere transition, depolymerization of acetylated microtubules, and formation of a smaller microtubule ring structure. D: HDAC6-mediated tubulin deacetylation, activation of the Rho GTPase effector PAK, actin reorganization, and formation of filopodia.
ferentially beneath the plasma membrane. The marginal band is composed of 8 -12 tightly bundled coils formed by some stable and several highly dynamic microtubules of mixed polarity (6) . Early during activation, the marginal band reorganizes and platelets change shape to become spheroids with filopodial extensions. Microtubules in the marginal band of resting platelets are heavily acetylated, and tubulin deacetylation takes place during platelet activation (8) . In their study, Aslan and colleagues place tubulin deacetylation more precisely within the sequence of events leading to fully activated platelets (1) . They show that tubulin is deacetylated once the signaling cascade leading to platelet activation has induced microtubule reorganization and platelet shape change. Thus, inhibition of Src family kinases (SFK), which are early signaling mediators essential for shape change, blocks tubulin deacetylation, while inhibition of signaling events following microtubule reorganization and shape change does not prevent tubulin deacetylation (Figure 1) .
The Aslan study then confirms that histone deacetylase 6 (HDAC6) is responsible for tubulin deacetylation in platelets and shows that HDAC6 is the major deacetylase in platelets. A key question is whether HDAC6 becomes activated to deacetylate microtubules when the marginal band reorganizes during platelet activation or, alternatively, whether HDAC6 is constitutively active and gains access to its substrate upon microtubule depolymerization. The fact that Aslan and colleagues do not detect a significant difference in HDAC activity between lysates of resting and activated platelets favors the latter possibility. Furthermore, the acetylated lysine 40 of ␣-tubulin, which is located at the luminal face of microtubules, would not facilitate HDAC6 access (9) . In addition, several studies have shown that microtubule depolymerization takes place during platelet activation. Thus, HDAC6, shown by Aslan and colleagues to be localized at the marginal band as well as in the platelet interior of resting platelets, may be waiting in a fully active state for microtubule depolymerization during platelet activation to attain access to its preferred substrate, depolymerized tubulin (5). This scenario is also compatible with the previous demonstration that nocodazole-induced depolymerization of the platelet marginal band leads to tubulin deacetylation, while acetylation is maintained during platelet activation when microtubules are stabilized with taxol (8) .
Another important observation made in this study of Aslan and colleagues is that activation of the Rho GTPase effector molecule PAK, induced after platelet activation with collagenrelated peptide (CRP), is blocked by HDAC6 inhibition. As a consequence, phosphorylation of downstream target kinases, all implicated in signaling processes during platelet activation, is also abolished. As discussed below, there are several potential explanations for the effects observed after HDAC6 inhibition but one intriguing possibility is that tubulin deacetylation serves as a checkpoint and is necessary for the subsequent steps of the activation sequence to proceed. In a sensor-signaleffector mechanism, the presence of unpolymerized, acetylated tubulin may prevent Rho GTPase effectors from rearranging the actin part of the cytoskeleton and allow transiently activated platelets to return to the resting state.
Aslan and colleagues further show that HDAC6 inhibition alters marginal band organization in resting platelets as well as microtubule reorganization during platelet activation. It also reduces platelet aggregation induced by CRP. The observed effects may be directly linked to microtubule hyperacetylation or the hyperacetylation of another HDAC6 substrate. Alternatively, the presence of HDAC6 in a catalytically inactive state could interfere with molecular processes, as observed by Zilberman et al. (11) in nucleated cells. Such an interpretation would also explain why Aslan et al. observe impaired platelet activation responses after HDAC6 inhibition, while it has previously been shown that HDAC6 deficiency leads to an enhanced activation response in terms of platelet spreading (8) . Another explanation for these divergent observations could be that HDAC6-deficient platelets have established mechanisms to compensate for a potential deleterious effect of hyperacetylated tubulin allowing a normal or even increased activation capacity in knockout versus wild-type platelets. Future studies are needed to provide mechanistic insights necessary to unravel the precise role of HDAC6 in platelets.
In conclusion, Aslan and colleagues provide further evidence for the importance of protein lysine acetylation in platelets and continue to pave the way to a better understanding of tubulin acetylation in platelet physiology. Similar to protein phosphorylation, one may predict that there are more reports to come on the regulatory potential of lysine acetylation in platelets. Since molecular processes identified in platelets also take place in nucleated cells, these studies will not only be crucial for a better understanding of platelet physiology, but will also increase our general knowledge about protein lysine acetylation in the cytoplasm (7) . Research in this area is of particular importance since several HDAC6-specific or pan-HDAC inhibitors are either already approved as therapeutic agents or currently being tested in clinical trials for cancer therapies as well as autoimmune and inflammatory disorders (3, 4) .
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